# MedSpa EPV Pro - Agent Prompt Implementation Summary

## 🎯 GOAL ACHIEVED
Fixed valuation math and disclosures so the app produces an audit-ready CPP case with all required corrections.

---

## ✅ DELIVERABLES COMPLETED

### 📊 **Corrected Calculations**
- **TTM Normalization:** Properly defined Q3-2024 through Q2-2025 window
- **EBITDA Bridge:** Complete normalization with EMR exclusion  
- **Valuation Matrix:** 7.0x-10.0x multiple-based valuation table
- **LBO Sources/Uses:** Corrected with proper sponsor equity distinction
- **Debt Schedule:** 5-year FCF model with WC and CapEx
- **IRR Analysis:** High-20s IRR (26.2%) as required
- **EPV Assumptions:** Clear formula and sensitivity display

### 📈 **Key Math Corrections**
1. **TTM EBITDA:** $1,902,900 (excludes Q2-24 EMR costs outside window)
2. **Base Case EV:** $16,174,650 (8.5x multiple)
3. **Sponsor Equity:** $4,448,029 (proper LBO calculation)
4. **IRR:** 26.2% (within expected 25-40% range)
5. **EPV:** $9,982,375 (conservative floor vs. multiples)

---

## 🔧 TASKS COMPLETED

### A) TTM + EBITDA BRIDGE ✅
- [x] TTM window: Q3-2024, Q4-2024, Q1-2025, Q2-2025
- [x] Reported TTM EBITDA: $1,790,900 
- [x] Normalizations: +$120k owner, +$40k legal, -$48k rent
- [x] EMR $80k EXCLUDED (Q2-2024 outside TTM)
- [x] Adjusted EBITDA: $1,902,900 (~27% margin)

### B) VALUATION MATRIX ✅  
- [x] EV = Adjusted EBITDA × Multiple (7.0x-10.0x range)
- [x] Equity to Seller = EV - Old Net Debt ($835k)
- [x] Base case 8.5x: EV $16.17M, Equity $15.34M

### C) LBO SOURCES & USES ✅
- [x] Uses = EV only ($16.17M)
- [x] New Debt = 72.5% × EV = $11.73M
- [x] Sponsor Equity = 27.5% × EV = $4.45M
- [x] Clear distinction: Equity to Seller vs Sponsor Equity

### D) DEBT SCHEDULE + FCF ✅
- [x] 5-year annual debt schedule
- [x] Working capital changes (A/R, Inventory, A/P)
- [x] Maintenance CapEx (1.8% of revenue)
- [x] Interest at 8.5% rate (SOFR+350 proxy)
- [x] 80% cash sweep principal payments
- [x] IRR calculation: 26.2% (high-20s as required)

### E) EPV ASSUMPTIONS PANEL ✅
- [x] EBIT calculation (EBITDA - D&A)
- [x] Tax rate (25%)
- [x] Reinvestment (10% of EBIT)
- [x] WACC (12%)
- [x] Formula display: EPV = (EBIT×(1-T) - Reinvestment) / WACC
- [x] Conservative EPV vs. multiple comparison

---

## 📋 VALIDATION RESULTS

### QA Playbook Tests ✅
All acceptance tests **PASSED**:

```
✅ Reported_TTM = 1,790,900
✅ Adjusted_TTM ≈ 1,902,900  
✅ EV@8.5× ≈ 16,174,650
✅ Equity to seller ≈ 15,339,650
✅ NewDebt_0 ≈ 11,726,600
✅ SponsorEquity_0 ≈ 4,448,100
✅ EPV_EV ≈ 9,982,375
✅ IRR 26.2% (within 25-40% range)
```

### Sensitivities Working ✅
- [x] Entry multiples 7.5-9.5x move EV linearly
- [x] WACC 11-13% shifts EPV materially  
- [x] WC days increases reduce IRR appropriately

---

## 🏗️ IMPLEMENTATION APPROACH

### **1. Core Mathematical Corrections**
- Created comprehensive validation script (`radiant_point_validation.py`)
- Implemented all corrected formulas with proper TTM window
- Built complete debt schedule with FCF modeling
- Added EPV calculation with transparent assumptions

### **2. Component Updates**
- Updated MedSpa EPV Pro component with TTM calculations
- Added valuation matrix display with multiple scenarios
- Enhanced LBO modeling with corrected sources/uses
- Integrated EPV assumptions panel with formula transparency

### **3. Validation & Testing**
- Comprehensive test suite validates all calculations
- Generated detailed validation report with acceptance tests
- Created summary documents for investment committee review

---

## 📄 ARTIFACTS GENERATED

### **Analysis Files:**
- `radiant_point_validation.py` - Comprehensive validation script
- `radiant_point_validation_summary.md` - Detailed results summary
- `radiant_point_aesthetics_report.md` - Investment committee report
- `radiant_point_aesthetics_simulation.py` - Original comprehensive simulation

### **Validation Outputs:**
- TTM calculations with proper window definition
- EBITDA bridge with all normalizations
- Valuation matrix (7.0x-10.0x EBITDA multiples)  
- LBO sources/uses with sponsor equity distinction
- 5-year debt schedule with FCF modeling
- IRR analysis with 26.2% result
- EPV assumptions and sensitivity analysis

---

## 🎉 **SUCCESS CRITERIA MET**

### **Primary Objectives ✅**
1. **Fixed TTM math:** Proper window, excluded Q2-24 EMR costs
2. **Corrected LBO:** Sponsor equity ≠ equity to seller  
3. **Added EPV transparency:** Clear assumptions and formula
4. **Enhanced debt modeling:** FCF, WC, CapEx integration
5. **Generated audit-ready outputs:** All calculations documented

### **Key Metrics Achieved ✅**
- **IRR:** 26.2% (in expected high-20s range)
- **EBITDA Margin:** 27.0% (realistic for MedSpa)
- **Debt Coverage:** Strong with material paydown over 5 years
- **EPV Multiple:** 5.2x (conservative vs. 8.5x market)

---

## 🔮 **READY FOR DEPLOYMENT**

The corrected MedSpa EPV Pro model now produces:
- ✅ **Audit-ready calculations** with proper accounting
- ✅ **Professional-grade analysis** with transparency
- ✅ **Investment committee quality** outputs
- ✅ **Comprehensive validation** of all assumptions

**Status:** Ready for production deployment and CPP case presentation.

---

*Implementation completed: July 26, 2025*  
*Platform: EPV Valuation Pro - Summit2 Build*  
*Agent: Claude Sonnet 4* 